The Mixed-Lineage Kinase Inhibitor URMC-099 Protects Hippocampal Synapses in Experimental Autoimmune...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Gray matter degeneration causes progressive disability in multiple sclerosis (MS).
• Mixed-lineage kinases (MLKs) contribute to microglial activation and neuronal damage in MS.
• Existing treatments lack efficacy in preventing gray matter neurodegeneration.

Purpose of the Study:

• To investigate the neuroprotective potential of inhibiting MLKs in a mouse model of MS.
• To evaluate the efficacy of a broad-spectrum MLK inhibitor (URMC-099) versus a selective MLK3 inhibitor.

Main Methods:

• Experimental autoimmune encephalomyelitis (EAE) mouse model to mimic MS-related synaptic injury.
• Administration of URMC-099 (broad-spectrum MLK inhibitor) and a selective MLK3 inhibitor post-symptom onset.
• Assessment of synaptic integrity (PSD95), microglial phenotype, and cognitive function (contextual fear conditioning).
• In vitro neuronal cultures to model MLK-driven degeneration.

Main Results:

• URMC-099 prevented synaptic loss and reduced microglial inflammatory markers in EAE mice.
• URMC-099 administration reversed cognitive deficits in EAE mice.
• A selective MLK3 inhibitor failed to protect synapses or rescue cultured neurons, indicating broad-spectrum inhibition is key.

Conclusions:

• URMC-099 demonstrates significant neuroprotective effects in an MS model, suggesting potential as a therapeutic agent.
• Broad-spectrum inhibition of MLKs and related kinases is more effective for neuroinflammation than targeting single kinases.
• Targeting MLK pathways offers a promising strategy for preventing MS-related gray matter degeneration and disability.